Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
US8680131B2 · kind B2 · utility
2Cited by
9References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 24, 2013 |
| Grant date | Mar 25, 2014 |
| Priority date | — |
| Expiry date | Jul 24, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D231/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.